Oxford BioDynamics, Google Cloud Partner to Accelerate Cloud-Based Analytical Frameworks for Precision Medicine

Oxford BioDynamics (OBD) has partnered with Google Cloud to expand the capabilities of its 3D genomic biomarker technology. The collaboration aims to scale OBD’s analytical framework by leveraging Google Cloud’s infrastructure, enabling the biotech firm to provide high-throughput, AI-powered 3D genomic analytics to its partners in the pharmaceutical and biotechnology sectors.

The partnership will see Google Cloud provide cloud computing support, allowing OBD to enhance its proprietary EpiSwitch knowledge base and analytical tools. This move is part of OBD’s broader digital transformation strategy and is expected to facilitate faster access to predictive genomic insights for drug development and diagnostics.

Iain Ross, OBD’s Executive Chairman, said, “Working with Google Cloud allows OBD to rapidly scale its analytical capabilities, bringing it closer to delivering precision 3D genomics insights in real time.” He added, “We are excited to develop a powerful and interoperable platform that aligns with the future of cloud-native biomedical research.”

The resources provided by Google Cloud will support the deployment of containerized applications, integration with Google Cloud’s AI/ML tools, and the creation of secure, scalable data processing pipelines. These pipelines are designed to meet healthcare compliance standards, making OBD’s EpiSwitch platform more accessible to its industry partners and paving the way for future commercialization opportunities.

OBD’s EpiSwitch platform is a clinically validated technology that identifies regulatory changes in 3D genome architecture, which can be used to detect disease signatures and aid in target development.